{
    "clinical_study": {
        "@rank": "80496", 
        "arm_group": {
            "arm_group_label": "Diagnostic (MRI-TRUS fusion image-guided biopsy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies magnetic resonance imaging (MRI)-transrectal ultrasound\n      (TRUS) fusion image-guided prostate biopsy following radical prostatectomy in patients with\n      prostate cancer. Diagnostic procedures, such as MRI-TRUS fusion image-guided prostate biopsy\n      may help find and diagnose prostate cancer"
        }, 
        "brief_title": "Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Image-Guided Prostate Biopsy Following Radical Prostatectomy in Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate accuracy of the new image-guided targeted needle biopsy using the ex-vivo\n      human prostate as obtained from fresh radical prostatectomy specimens.\n\n      OUTLINE:  Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion\n      image-guided prostate biopsies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have biopsy-proven prostate cancer, or prostate-specific antigen (PSA)\n             >= 4 ng/ml or an abnormal digital rectal examination (DRE) if consented before\n             prostate biopsy\n\n          -  Subjects must have at least 2, preferably 3, pre-operative magnetic resonance imaging\n             (MRI)-identified malignant or benign lesions that measure between 10 mm and 15 mm in\n             diameter within the prostate\n\n          -  Subjects must have decided to have their prostate surgically removed\n\n        Exclusion Criteria:\n\n          -  Patients who do not give informed consent\n\n          -  Patients with extracapsular extension of their prostate cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764347", 
            "org_study_id": "4P-10-6", 
            "secondary_id": "NCI-2012-03037"
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (MRI-TRUS fusion image-guided biopsy)", 
                "description": "Undergo robotic radical prostatectomy", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (MRI-TRUS fusion image-guided biopsy)", 
                "description": "Undergo MRI-TRUS fusion image-guided prostate biopsy", 
                "intervention_name": "ultrasound-guided prostate biopsy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (MRI-TRUS fusion image-guided biopsy)", 
                "description": "Undergo MRI-TRUS fusion image-guided prostate biopsy", 
                "intervention_name": "magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "MRI", 
                    "NMR imaging", 
                    "NMRI", 
                    "nuclear magnetic resonance imaging"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033"
                }, 
                "name": "USC Norris Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Accuracy of Targeted Biopsies Using MRI-TRUS Fusion Guidance: Pilot Study on Ex Vivo Radical Prostatectomy Specimens", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Osamu Ukimura", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "A likelihood ratio test will be used to test for independence among lesions within a prostate (corresponding to a lack of systematic MRI-TRUS image distortion and implying that, overall, 1st biopsies to a lesion within one prostate are as likely to accurate as in another prostate).", 
                "measure": "Number of times the first biopsy needle is placed within 3.0 mm of the center lesion", 
                "safety_issue": "No", 
                "time_frame": "One month after last patient enrolled is taken off study"
            }, 
            {
                "description": "A likelihood ratio test will be used to test for independence among lesions within a prostate (corresponding to a lack of systematic MRI-TRUS image distortion and implying that, overall, 1st biopsies to a lesion within one prostate are as likely to accurate as in another prostate).", 
                "measure": "Number of times the second biopsy needle is placed within 3.0 mm of the center lesion", 
                "safety_issue": "No", 
                "time_frame": "One month after last patient enrolled is take off study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A nested (random effects) analysis of variance (ANOVA) will be used to analyze the distance of the first needle from the center of the lesion. Standard error or 95% confidence interval will be calculated.", 
                "measure": "Average distance of the first needle to the center of the lesion", 
                "safety_issue": "No", 
                "time_frame": "One month after last patient enrolled is taken off study"
            }, 
            {
                "description": "A nested (random effects) ANOVA will be used to analyze the distance of the first needle from the center of the lesion.", 
                "measure": "Average distance of the second needle from the first needle minus 2.0 mm", 
                "safety_issue": "No", 
                "time_frame": "One month after last patient enrolled is taken off study"
            }, 
            {
                "description": "A nested (random effects) ANOVA will be used to analyze the distance of the first needle from the center of the lesion.", 
                "measure": "Average distance of the third needle from the first needle minus 2.0 mm", 
                "safety_issue": "No", 
                "time_frame": "One month after last patient enrolled is taken off study"
            }
        ], 
        "source": "University of Southern California", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Southern California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}